Form 2150 R1.0: CMV / EBV / ADV / HHV-6 / BK Viral Infection Diagnostic and Treatment Form CRID: Center: **Key Fields** Sequence Number: CIBMTR Center Number: CIBMTR Research ID: Event date: _____ ☐ Baseline ☐ 100 day ☐ 6 months ☐ 1 year ☐ 2 years ☐ > 2 years Specify: Infection Episode Questions: 1 - 31 1 Organism 304 Adenovirus C 341 BK Virus 303 Cytomegalovirus (CMV) 318 Epstein-Barr Virus (EBV) 317 Human herpesvirus 6 (HHV-6) 2 Date of diagnosis of infection: ____ - __ - __ - __ Select all diagnostic tests used to determine the diagnosis of viral infection with a positive result. If test was performed, select every site from which the test was obtained and positive. 3 Polymerase chain reaction (PCR) assay C Yes C No 4 Specify sample source (that supported the diagnosis of infection) (check all that apply) Blood (includes whole blood, bone marrow, serum, or plasma) ☐ Bronchial fluid (BAL) \Box Cerebrospinal fluid (CSF) Pericardial fluid Stool Tissue Urine Other **5** Specify other sample source: 6 Date sample collected: ____-_-_-Detection in blood / serum by PCR 7 Highest viral copies reported: (since date of diagnosis) C copies/mL C copies/L C IU/mL C IU/L 8 Date highest viral load detected: - -PCR Tissue Sample(s) (1) Questions: 9 - 11 Specify tissue for PCR assay:

9 Specify tissue

Central nervous system (CNS) (includes brain)

GI tract (esophagus, stomach, intestines)

C Heart / myocardium

C Liver

C Lung

C Lymph node

Skin

Spleen

Other

10 Specify other tissue:

11 Date sample collected: ____

12 Culture

C Yes C No

Form 2150 R1.0: CMV / EBV / ADV / HHV-6 / BK Viral Infection Diagnostic and Treatment Form Center: 13 Specify sample source (that supported the diagnosis of infection) (check all that apply) ☐ Blood (includes whole blood, bone marrow, serum, or plasma) ☐ Bronchial fluid (BAL) Cerebrospinal fluid (CSF) \Box Pericardial fluid Г Stool Г Tissue Urine Other **14** Specify other sample source: Specify tissue: 15 Specify tissue (check all that apply) (includes brain) Central nervous system (CNS) (esophagus, stomach, intestines) ☐ GI tract Heart / myocardium Liver Lung Lymph node Skin Spleen Other 16 Specify other tissue: 17 Were there histopathology findings of viral cytopathic changes? (on biopsy) C Yes C No 18 Specify biopsy site (that supported the diagnosis of infection) (check all that apply) Central nervous system (CNS) (includes brain) (esophagus, stomach, intestines) \Box Heart / myocardium \Box Liver ☐ Lung Lymph node \Box Skin Γ Spleen \Box Other 19 Specify other site: 20 Were immunohistochemistry (IHC) stains obtained on tissue biopsy? (that supported the diagnosis of infection) C Yes C No 21 Specify biopsy site (that supported the diagnosis of infection) (check all that apply) (includes brain) Central nervous system (CNS) GI tract (esophagus, stomach, intestines) Heart / myocardium Г Liver Г Lung Lymph node Skin Spleen Other 22 Specify other site: 23 Radiographic findings of infection (e.g. X-ray, CT, PET, or MRI)

C Yes C No

Form 2150 R1.0: CMV / EBV / A Center: CRII	D:	
24 Specify imaging site (that supported the dia Central nervous system (CNS) GI tract (esophagus, stomation Heart / myocardium Liver Lung Lymph node Skin Spleen Other	(includes brain)	
25 Specify other site:		
Select all clinical signs present on the date (± 1 d 26 Requiring oxygen	day) of diagnosis of infection	
C Yes C No 27 Hepatomegaly C yes C no		
28 Splenomegaly C yes C no		
29 Diarrhea		
30 Neurologic symptoms (e.g. confusion, irritability, s	seizures, drowsiness)	
31 Enlarged lymph nodes / lymphadenopathy C Yes C No		
	Hematologic Findings at Diagnosis of Infection	Questions: 32 - 50
Provide values closest to the date of diagnosis o	of the infection (± 7 days)	
32 WBC C Known C Unknown		
32 WBC	C x 109/L (x 103/mm ³) C x 106/L	
32 WBC C Known C Unknown 33 34 Neutrophils C Known C Unknown	C x 109/L (x 103/mm³)	
32 WBC C Known C Unknown 33 34 Neutrophils	C x 109/L (x 103/mm³)	
32 WBC C Known C Unknown 33 34 Neutrophils C Known C Unknown 35	C x 109/L (x 103/mm³)	
32 WBC C Known C Unknown 33 34 Neutrophils C Known C Unknown 35 % 36 Monocytes C Known C Unknown 37 % 38 Lymphocytes C Known C Unknown Unknown Unknown Unknown	C x 109/L (x 103/mm³)	
32 WBC C Known C Unknown 33 34 Neutrophils C Known C Unknown 35 % 36 Monocytes C Known C Unknown 37 % 38 Lymphocytes C Known C Unknown 39 % 40 Platelets	C x 109/L (x 103/mm³)	
32 WBC C Known C Unknown 33 34 Neutrophils C Known C Unknown 35 % 36 Monocytes C Known C Unknown 37 % 38 Lymphocytes C Known C Unknown 39 %	C x 109/L (x 103/mm³)	
32 WBC	C x 109/L (x 103/mm³) C x 106/L C x 109/L (x 103/mm³)	
32 WBC C Known C Unknown 33 34 Neutrophils C Known C Unknown 35 36 Monocytes C Known C Unknown 37 38 Lymphocytes C Known C Unknown 39 W 40 Platelets C Known C Unknown 41 42 Serum creatinine	C x 109/L (x 103/mm³) C x 109/L (x 103/mm³) C x 109/L (x 103/mm³) C x 108/L C mg/dL C mmol/L C μmol/L	
32 WBC C Known C Unknown 33	С x 109/L (x 103/mm³) С x 106/L С x 109/L (x 103/mm³) С x 106/L С mg/dL С mmol/L С µmol/L С mg/dL С mmol/L С µmol/L	
32 WBC C Known C Unknown 33	С x 109/L (x 103/mm³) С x 106/L С x 109/L (x 103/mm³) С x 106/L С mg/dL С mmol/L С µmol/L С mg/dL С mmol/L С µmol/L	
32 WBC C Known C Unknown 33 34 Neutrophils C Known C Unknown 35	C x 109/L (x 103/mm3) C x 106/L C x 109/L (x 103/mm3) C x 106/L C mg/dL C mmol/L C µmol/L C mg/dL C mmol/L C µmol/L	
32 WBC C Known C Unknown 33 34 Neutrophils C Known C Unknown 35 36 Monocytes C Known C Unknown 37 38 Lymphocytes C Known C Unknown 39 W 40 Platelets C Known C Unknown 41 42 Serum creatinine C Known C Unknown 43 44 Upper limit of normal for your institution: 45 ALT (SGPT) C Known C Unknown 46 Unknown	С x 109/L (x 103/mm3) С x 106/L С x 109/L (x 103/mm3) С x 106/L С mg/dL С mmol/L С µmol/L С mg/dL С mmol/L С µmol/L	

50 Date sample collected: ______-___

Form 2150 R1.0: CMV / EBV / ADV / HHV-6 / BK Viral Infection Diagnostic and Treatment Form

Center: CRID:

Specify artificing period for this recipient hose addition. If the recipient necessarily the analysis record the data that the wediciation started. Did the recipient necessary thereby between 7 days prior to the data of infection diagnosis and the data of contact for this reporting period? (**Yes** *No.** Antificial drugs** *Oscillation** *Oscillation*	Inerapy	Questions: 51 - 76
S2 Antivital drugs		recipient received the
### Antiform drugs (*)		
53 Specify antivirial drug	·	
53 Specify antivirial drug	Antiviral drugs (1)	Questions: 52 57
Marthanir (Value) Eminication (CMXOD) Calludovic (Value) Foscarret (Foscarrit) Ganocidovic (Cytovene) Letermovic (Prevymis) 84 Specty other antiviral drug 85 Was therapy started more than 7 days prior to the date of infection diagnosis? (**Yes** C No.** 86 Date started:		Questions. 55 - 57
55 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 66 Date started: C Date estimated 57 Was this therapy still being given at 30 days (£ 3 days) after the date of diagnosis of infection? C Yes C No 69 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 60 Date started: C Date estimated 61 Was this therapy still being given at 30 days (£ 3 days) after the date of diagnosis of infection? C Yes C No 62 Rituration (Rituran) C Yes C No 63 Was meapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 64 Rituration (Rituran) C Yes C No 65 Was this therapy still being given at 30 days (£ 3 days) after the date of diagnosis of infection? C Yes C No 65 Was this therapy still being given at 30 days (£ 3 days) after the date of diagnosis? C Yes C No 66 NO3 (polydonal N immuns globulin) C Yes C No 67 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 68 Date started: C Date estimated 69 Was this therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 70 Cytogam (CMM typerimmune gamma globulin) C Yes C No 71 Was therapy started more than 7 days prior to the date of infection diagnosis of infection? C Yes C No 72 Date estimated 73 Was this therapy started more than 7 days prior to the date of infection diagnosis of infection? C Yes C No 74 Celular therapy started more than 7 days prior to the date of infection diagnosis of infection? C Yes C No 75 Other drug used to treat this infection C Yes C No 76 Specify: C No 76 Specify: C Specify: C Date estimated	Acyclovir (Zovirax) Brincidofovir (CMX-001) Cidofovir (Vistide) Foscarnet (Foscavir) Ganciclovir (Cytovene)	Letermovir (Prevymis)
57 Was this therapy still being given at 30 days (s. 3 days) after the date of diagnosis of infection? Yes No S9 Was membrany started more than 7 days prior to the date of infection diagnosis? Yes No 60 Date started: 10 Yes No 62 Rituximab (Rituxan) Yes No 63 Was therapy started more than 7 days prior to the date of infection diagnosis of infection? 64 Date started: Yes No 65 Was the started: Yes No 66 Ab Date started: Yes No 67 Wes Ino 68 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 68 Date started: Yes No 69 Was this therapy still being given at 30 days (s. 3 days) after the date of diagnosis of infection? Yes No 68 MS glopyclonal IV immune globulin) Yes No 68 MS polyclonal IV immune globulin) Yes No 68 Was this therapy still being given at 30 days (s. 3 days) after the date of diagnosis of infection? Yes No 69 Was this therapy still being given at 30 days (s. 3 days) after the date of diagnosis of infection? Yes No 69 Was this therapy still being given at 30 days (s. 3 days) after the date of diagnosis of infection? Yes No 69 Was this therapy still being given at 30 days (s. 3 days) after the date of diagnosis of infection? Yes No 70 Cytogam (CMV hyperimune gamma globulin) Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 72 Date started: Yes No 73 Was this therapy started more than 30 days (s. 3 days) after the date of diagnosis of infection? Yes No 74 Cellulat therapy (e.g., virus specific T-cells, DL) Yes No 75 Other drug used to treat this infection Yes No 76 Specify:	55 Was therapy started more than 7 days prior to the date of infection diagnosis?	
S8 Was combination chemotherapy used to treat EBV-associated malignancies? (e.g. CHOP, etc.) Yes No S9 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 60 Date started: 61 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 62 Rituximab (Rituxan) Yes No 63 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 64 Date started: Yes No 65 Mild (polyclonal IV immune globulin) Yes No 66 Mild (polyclonal IV immune globulin) Yes No 68 Date started: Yes No 69 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 69 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 67 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 70 Cytogam (CMV hyperimmune gamma globulin) Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 72 Date started: Yes No 73 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 74 Cellular therapy (e.g., vinus specific T-cells, DLI) Yes No 75 Other drug used to treat this infection Yes S no 76 Specify: Yes No 77 Specify:	56 Date started: Date estimated	
S9 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 60 Date started: No 61 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 62 Rituximab (Rituxan) Yes No 63 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 64 Date started: No 65 IVIG (polyclonal IV immune globulin) Yes No 66 IVIG (polyclonal IV immune globulin) Yes No 68 Date started: No 68 Date started: No 69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 68 Date started: No 69 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 70 Cytogam (CMM hyperimmune gamma globulin) Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 72 Date started: Date estimated 73 Was this therapy started more than 7 days prior to the date of infection diagnosis? Yes No 74 Cellust therapy (e.g., virus specific T-cells, DLI) Yes Also complete Pre-CTED Form 4000 No No 75 Other days used to treat this infection Yes No 76 Specify: No 77 Specify: No 76 Specify: No 76 Specify: No 76 Specify: No No No No No No No No No N		
S9 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 60 Date started: No 61 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 62 Rituximab (Rituxan) Yes No 63 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 64 Date started: No 65 IVIG (polyclonal IV immune globulin) Yes No 66 IVIG (polyclonal IV immune globulin) Yes No 68 Date started: No 68 Date started: No 69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 68 Date started: No 69 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 70 Cytogam (CMM hyperimmune gamma globulin) Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 72 Date started: Date estimated 73 Was this therapy started more than 7 days prior to the date of infection diagnosis? Yes No 74 Cellust therapy (e.g., virus specific T-cells, DLI) Yes Also complete Pre-CTED Form 4000 No No 75 Other days used to treat this infection Yes No 76 Specify: No 77 Specify: No 76 Specify: No 76 Specify: No 76 Specify: No No No No No No No No No N		
60 Date started: Date estimated 61 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection?		
61 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes C No 63 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 64 Date started: Date estimated 65 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes C No 66 IVIG (polyclonal IV immune globulin) C yes C no 67 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 68 Date started: Date estimated 69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes C No 68 Date started: Date estimated 69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes C No 70 Cytogam (CMV hypertimnume gamma globulin) C Yes C No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 72 Date started: Date estimated 73 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes C No 74 Cellular therapy (e.g., virus specific T-cells, DLI) C yes - Also complete Pre-CTED Form 4000 C no 75 Other drug used to treat this infection C yes C no		
C Yes C No 62 Rituximab (Rituxina) C yes C no 63 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 64 Date started: C Yes C No 65 IVIS (polyclonal IV immune globulin) C yes C no 67 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 68 Date started: C Yes C No 69 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 69 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes C No 70 Cytogam (CMV hyperimmune gamma globulin) C Yes C No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes C No 72 Date started: C Yes C No 73 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes C No 74 Cellular therapy (e.g., virus specific T-cells, DLI) C Yes C No 75 Other drug used to treat this infection C Yes C no 76 Specify: ———————————————————————————————————	60 Date started: Date estimated	
63 Was therapy started more than 7 days prior to the date of infection diagnosis? 'Yes 'No 64 Date started: Date estimated 65 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? 'Yes 'No 66 WG (polyclonal IV immune globulin) 'yes 'No 67 Was therapy started more than 7 days prior to the date of infection diagnosis? 'Yes 'No 68 Date started: Date estimated 69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? 'Yes 'No 70 Cytogam (CMV hyperimmune gamma globulin) 'Yes 'No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? 'Yes 'No 72 Date started: Date estimated 73 Was therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? 'Yes 'No 72 Date started: Date estimated 73 Was therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? 'Yes 'No 74 Cellular therapy (e.g., virus specific T-cells, DLI) 'yes - Also complete Pre-CTED Form 4000 'No 75 Other drug used to treat this infection 'yes 'no 76 Specify:		
G Yes No 64 Date started: Date estimated 65 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes No 66 IMG (polyclonal IV immune globulin) yes No 67 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 68 Date started: Date estimated 69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 70 Cytogam (CMV hyperimmune gamma globulin) Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 72 Date started: Date estimated 73 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 74 Cellular therapy (e.g., virus specific T-cells, DLI) Yes - No 75 Other drug used to treat this infection yes no 76 Specify:	·	
65 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 66 IVIG (polyclonal IV immune globulin) Yes No 67 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 68 Date started: Yes No 70 Cytogam (CMV hyperimunue gamma globulin) Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis of infection? Yes No 72 Date started: Yes No 73 Was this therapy started more than 7 days prior to the date of infection diagnosis? Yes No 74 Cellular therapy (e.g., virus specific T-cells, DLI) Yes - Also complete Pre-CTED Form 4000 no 75 Other drug used to treat this infection Yes No 76 Specify: ———————————————————————————————————		
C Yes C No 66 IVIG (polyclonal IV immune globulin) C yes C no 67 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes No 68 Date started: Date estimated 69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes No 70 Cytogam (CMV hyperimmune gamma globulin) C Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? C Yes No 72 Date started: Date estimated 73 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes No 74 Cellular therapy (e.g., virus specific T-cells, DLI) C yes -Also complete Pre-CTED Form 4000 C no 75 Other drug used to treat this infection C yes C no 76 Specify:	64 Date started: Date estimated	
67 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 68 Date started: Date estimated 69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 70 Cytogam (CMV hyperimmune gamma globulin) Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 72 Date started: Date estimated 73 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 74 Cellular therapy (e.g., virus specific T-cells, DLI) Yes - Also complete Pre-CTED Form 4000 no 75 Other drug used to treat this infection Yes No 76 Specify:		
C Yes No 68 Date started: Date estimated 69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? C Yes No 70 Cytogam (CMV hyperimmune gamma globulin) Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 72 Date started: Date estimated 73 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 74 Cellular therapy (e.g., virus specific T-cells, DLI) Yes - Also complete Pre-CTED Form 4000 no 75 Other drug used to treat this infection yes no 76 Specify:	" · •	
69 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 70 Cytogam (CMV hyperimmune gamma globulin) Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 72 Date started: Yes No 73 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 74 Cellular therapy (e.g., virus specific T-cells, DLI) yes - Also complete Pre-CTED Form 4000 no 75 Other drug used to treat this infection yes no 76 Specify:		
70 Cytogam (CMV hyperimmune gamma globulin) Yes No 71 Was therapy started more than 7 days prior to the date of infection diagnosis? Yes No 72 Date started: Date estimated 73 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 74 Cellular therapy (e.g., virus specific T-cells, DLI) yes - Also complete Pre-CTED Form 4000 no 75 Other drug used to treat this infection yes no 76 Specify:	68 Date started: Date estimated	
The started is a started from the starte		
Test No Tes		
73 Was this therapy still being given at 30 days (± 3 days) after the date of diagnosis of infection? Yes No 74 Cellular therapy (e.g., virus specific T-cells, DLI) yes - Also complete Pre-CTED Form 4000 no 75 Other drug used to treat this infection yes no 76 Specify:		
74 Cellular therapy (e.g., virus specific T-cells, DLI) yes - Also complete Pre-CTED Form 4000 no 75 Other drug used to treat this infection yes no 76 Specify:	72 Date started: Date estimated	
yes - Also complete Pre-CTED Form 4000 no 75 Other drug used to treat this infection yes no 76 Specify:		
75 Other drug used to treat this infection yes no 76 Specify:		
76 Specify:	C no	
Infaction Status at the Time of Evaluation for this Panarting Pariod	76 Specify:	
Questions: // - //	Infection Status at the Time of Evaluation for this Reporting Period	Questions: 77 - 77

CIBMTR Form 2150 revision 1.0 last updated Friday, April 27, 2018 Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved.

What we the 155 after a table of the 150 after the 150 aft
Vhat was the infection status at the time of evaluation for this reporting period?
Ongoing Improved Resolved Unknown
Name:
Name:
il address:

Form 2150 R1.0: CMV / EBV / ADV / HHV-6 / BK Viral Infection Diagnostic and Treatment Form

CRID:

Center:

Date: _